MX2019011808A - Endolisinas de gram-negativas modificadas. - Google Patents

Endolisinas de gram-negativas modificadas.

Info

Publication number
MX2019011808A
MX2019011808A MX2019011808A MX2019011808A MX2019011808A MX 2019011808 A MX2019011808 A MX 2019011808A MX 2019011808 A MX2019011808 A MX 2019011808A MX 2019011808 A MX2019011808 A MX 2019011808A MX 2019011808 A MX2019011808 A MX 2019011808A
Authority
MX
Mexico
Prior art keywords
relates
present
bacteriophages
vectors
nucleic acids
Prior art date
Application number
MX2019011808A
Other languages
English (en)
Inventor
Biebl Manfred
Griessl Martin
Original Assignee
Sasinapas Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sasinapas Co Ltd filed Critical Sasinapas Co Ltd
Publication of MX2019011808A publication Critical patent/MX2019011808A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462Lysozyme (3.2.1.17)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00Bacteriophages
    • C12N2795/00011Details
    • C12N2795/10011Details dsDNA Bacteriophages
    • C12N2795/10111Myoviridae
    • C12N2795/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

La presente invención se refiere en general al campo de las enzimas antimicrobianas. En particular, la presente invención se refiere a un polipéptido que comprende la secuencia de aminoácidos de una endolisina globular de Gramnegativas y la secuencia de aminoácidos de un dominio de unión a la pared celular de i) una endolisina modular de Gram-negativas o ii) una proteína de la cola/placa base de un bacteriófago. La presente invención también se refiere a los ácidos nucleicos, vectores, bacteriófagos, células huésped y composiciones correspondientes. La presente invención también se refiere al uso de dichos polipéptidos, ácidos nucleicos, vectores, bacteriófagos, células huésped y composiciones en procedimientos para el tratamiento del cuerpo humano o animal mediante cirugía o terapia o en procedimientos de diagnóstico practicados en el cuerpo humano o animal. Los polipéptidos, ácidos nucleicos, vectores, bacteriófagos, células huésped y composiciones de acuerdo con la invención también se pueden utilizar como un antimicrobiano en, por ejemplo, alimentos o piensos, en cosméticos, o como un agente desinfectante.
MX2019011808A 2017-04-03 2018-04-02 Endolisinas de gram-negativas modificadas. MX2019011808A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2017051886 2017-04-03
PCT/IB2018/052253 WO2018185634A1 (en) 2017-04-03 2018-04-02 Engineered gram-negative endolysins

Publications (1)

Publication Number Publication Date
MX2019011808A true MX2019011808A (es) 2020-01-09

Family

ID=58547758

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011808A MX2019011808A (es) 2017-04-03 2018-04-02 Endolisinas de gram-negativas modificadas.

Country Status (11)

Country Link
US (2) US11208643B2 (es)
EP (1) EP3607062A1 (es)
JP (2) JP2020515295A (es)
KR (1) KR20200012844A (es)
CN (1) CN110651044A (es)
AU (1) AU2018248060B2 (es)
CA (1) CA3059019A1 (es)
IL (1) IL269442A (es)
MX (1) MX2019011808A (es)
SG (1) SG11201908657VA (es)
WO (1) WO2018185634A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11208646B2 (en) * 2016-05-27 2021-12-28 Sasinapas Co., Ltd. Endolysin variant
MX2021013491A (es) * 2019-05-08 2022-02-21 Phagomed Biopharma Gmbh Nuevas endolisinas de gardnerella y usos de las mismas.
CN112724257B (zh) * 2019-10-14 2023-09-19 江西缘生生物科技有限公司 具有强杀菌效果的杂合抗菌蛋白及其应用
CN115605587A (zh) * 2020-03-11 2023-01-13 特卢姆治疗有限公司(Es) 新型重组溶素及其在治疗革兰氏阴性菌感染中的用途
WO2021235876A1 (ko) 2020-05-22 2021-11-25 주식회사 라이센텍 신규한 폴리펩타이드, 융합 폴리펩타이드, 및 이를 포함하는 그람음성균에 대한 항생제
CN114478794A (zh) * 2020-11-13 2022-05-13 江苏万邦医药科技有限公司 幽门螺旋杆菌噬菌体裂解系统及其表达纯化方法和应用
US20220387563A1 (en) * 2021-04-19 2022-12-08 Lysentech Co., Ltd. Novel polypeptides and antibiotics against Gram-negative bacterium comprising the same
KR20230024845A (ko) 2021-08-09 2023-02-21 주식회사 레고켐 바이오사이언스 신규 항생제 및 이의 용도
CN113801864B (zh) * 2021-08-13 2023-09-26 青岛农业大学 一种用于编码溶酶菌lysin6的基因及其应用
US11548917B1 (en) * 2021-11-24 2023-01-10 Intron Biotechnology, Inc. Antibacterial composition effective in treating gram negative bacterial infections and method for preparing the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8816693D0 (en) 1988-07-13 1988-08-17 Agricultural & Food Res Viral enzyme & gene
GB0815484D0 (en) 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
BRPI1015203B1 (pt) * 2009-06-26 2021-06-01 Lysando Ag Proteína de fusão composta por uma endolisina e uma extensão de peptídeo anfifática, usos da mesma e composição farmacêutica que compreende a dita proteína
KR20170024129A (ko) * 2009-06-26 2017-03-06 카톨리에케 유니버시테이트 루벤 항균제
EP2468856A1 (en) * 2010-12-23 2012-06-27 Lysando Aktiengesellschaft Antimicrobial Agents
CN103635584B (zh) * 2011-04-12 2017-10-27 冈戈根股份有限公司 嵌合抗菌多肽
WO2015070911A1 (en) * 2013-11-14 2015-05-21 Lysando Ag Modified kz144 endolysin sequence
WO2015070912A1 (en) * 2013-11-14 2015-05-21 Lysando Ag Modified el188 endolysin sequence

Also Published As

Publication number Publication date
AU2018248060A1 (en) 2019-10-03
US20210108185A1 (en) 2021-04-15
KR20200012844A (ko) 2020-02-05
WO2018185634A1 (en) 2018-10-11
CA3059019A1 (en) 2018-10-11
US20220064616A1 (en) 2022-03-03
AU2018248060B2 (en) 2024-05-23
EP3607062A1 (en) 2020-02-12
CN110651044A (zh) 2020-01-03
IL269442A (en) 2019-11-28
JP2020515295A (ja) 2020-05-28
SG11201908657VA (en) 2019-10-30
US11208643B2 (en) 2021-12-28
JP2023062086A (ja) 2023-05-02

Similar Documents

Publication Publication Date Title
MX2019011808A (es) Endolisinas de gram-negativas modificadas.
MX2019005979A (es) Peptidos modificados.
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
MX2019009720A (es) Metodos y composiciones para la transferencia de genes a traves de la vasculatura.
MX2023003255A (es) Polipeptidos efectores crispr-cas y metodos para su uso.
GB201018518D0 (en) Novel endolysin
MX2012002216A (es) Nueva endolisina obpgplys.
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
WO2017058892A3 (en) Methods and compositions for antibody-evading virus vectors
MX2009012650A (es) Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
WO2010065824A3 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP2009536033A5 (es)
FI3778885T3 (fi) Muokattujen ihmisen arginaasien koostumuksia ja menetelmiä syövän hoitamiseksi
EP3450568A3 (en) Vectors conditionally expressing protein
IN2012DN03368A (es)
MX2020006098A (es) Lisinas y sus derivados con actividad bactericida contra pseudomona aeruginosa, en la presencia de suero humano.
WO2017125585A3 (en) Novel polypeptides and medical uses thereof
MX2020000018A (es) Potencializacion de componentes sanguineos de actividad anti-bacteriana de proteina litica y metodos y usos de estos.
MX2022007858A (es) Polipeptidos efectores crispr-cas y metodos de uso de estos.
WO2009046464A8 (en) Articular cartilage gene therapy with recombinant vector encoding bmp-7
MX2021009696A (es) Vectores de genoterapia para el tratamiento de la enfermedad de danon.
WO2020163743A8 (en) Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
EA201391444A1 (ru) Вариант инсектицидного гена axmiи способы его применения
ES2659586T3 (es) Proteínas de fusión quiméricas y partículas similares a virus de VP2 de Birnavirus
EA201991233A1 (ru) Новый эндолизин